Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee proce
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... 2014 Pomerantz LLP has filed a class ... (NASDAQ: EDAP ) and certain of its ... Court, Southern District of New York ... a class consisting of all persons or entities who ... 30, 2014, inclusive (the "Class Period"). This class action seeks ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... Inc. (pronounced dot decimal), an innovative manufacturer of patient-specific ... 510(k) clearance from the FDA to market electron apertures ... now available to radiation oncology centers across the U.S. ... known as electron ,cutouts, by radiation therapy departments -- ...
... - Digital issue looks inside the minds, lives ... Journal of Emergency Medical Services ( JEMS ) ... issue featuring first-person accounts of responders who were thrust into ... terrorists invaded their response districts - and their lives - ...
Cached Medicine Technology:Florida Medical Device Manufacturer Announces New Product Release for Radiation Therapy 2Out of the Darkness 2Out of the Darkness 3
(Date:9/1/2014)... The Outlier Series announced the next ... content from one of the exceptional women featured in ... Game Changers . The title of the upcoming mini ... Jenny McClendon . McClendon is currently a full-time physician’s ... star of WeTV show, Raising Sextuplets. , Jenny was ...
(Date:9/1/2014)... Psychogenic Non-epileptic Seizures (PNES), also known as non-epileptic ... have devastating effects on those who develop it. These ... are not produced by electrical anomalies in the brain ... that the numbers of persons suffering PNES may be ... , Dr. Lorna Myers, Director of the Northeast Regional ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
(Date:8/31/2014)... Mesa, AZ (PRWEB) August 31, 2014 ... in Mesa, Arizona, prescribes sublingual immunotherapy to help his ... includes tree nut allergies. Dr. Agren said that it ... nut-based foods and, in many cases, restored peace of ... can lead to a host of symptoms, including rashes, ...
(Date:8/31/2014)... Orem, UT (PRWEB) August 31, 2014 ... a number of states have proposed legislation to require ... so consumers can make informed purchasing decisions that affect ... As an industry leader advocating for stringent measures to ... launch of its “Information, Communication, Engagement” (I.C.E.) initiative with ...
Breaking Medicine News(10 mins):Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 2Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 3Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3
... Annual Scientific Meeting: Nearly 5,300 physicians, scientists and ... IR" showcases the exciting ways that interventional radiologists ... on new research related to multiple sclerosis and ... From Science to Practice." There will be debates ...
... Feb. 9 (HealthDay News) -- Zebras evolved from all ... distract them from feeding, a new study contends. ... black and white stripes are the least-attractive hide pattern ... horseflies. The researchers found that horseflies are drawn ...
... a study to be presented today at the Society ... in Dallas, Texas, researchers will report findings that women ... appear to know little about the risks and benefits ... of labor to attempt a vaginal delivery, and that ...
... including the mapping of the genomes of more than ... base pairs of sequence data. The leading scientific journal ... the scientific breakthroughs of 2011. Large-scale genome sequencing is ... agricultural research. Henry Yang, Executive Managemer of BGI, ...
... WEDNESDAY, Feb. 8 (HealthDay News) -- Middle-school kids who participate ... than other kids, new research finds. Yet, students with ... apparent influence of peers is more pronounced among girls. ... smoking behavior of others even though there might be a ...
... Researchers at Virginia Commonwealth University Medical Center,s VCU ... Center (Richmond, VA) and Old Dominion University (Norfolk, ... 1 protein (WT1) results in downregulation of CD97 ... reduces the characteristic invasiveness exhibited by glial tumor ...
Cached Medicine News:Health News:Media alert: Society of Interventional Radiology's 37th Annual Scientific Meeting 2Health News:Bug Bites May Have Caused Zebras' Stripes 2Health News:Study finds pregnant women with prior cesarean choose the delivery method preferred by their doctor 2Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 2Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 3Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 2Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: